Pulmonary sclerosing hemangioma associated with familial adenomatous polyposis.

Department of Clinical Pathology, Toyooka Hospital, Toyooka, Hyogo, Japan.
Human Pathlogy (Impact Factor: 2.84). 07/2004; 35(6):764-8. DOI: 10.1016/j.humpath.2004.02.003
Source: PubMed

ABSTRACT A 45-year-old woman presented with asymptomatic solid tumor in the lower right lobe of the lung. Histologically, the tumor comprised a monolayer of surface cells and round stromal cells displaying sclerotic areas. Immunohistochemical studies suggested a diagnosis of sclerosing hemangioma. Interestingly, morular lesions were also observed. Analyses of the gastrointestinal (GI) tract showed mild familial adenomatous polyposis (FAP) and numerous fundal gland polyps, indicating attenuated FAP (AFAP). All components of the sclerosing hemangioma displayed aberrant nuclear and cytoplasmic expression of beta-catenin. However, such findings were much weaker in adenomas of the GI tract and were barely observed in fundal gland polyps. These results strongly suggest an association between sclerosing hemangioma and the AFAP. To the best of our knowledge, this is only the second report of lung tumor associated with FAP and is the first describing an association with sclerosing hemangioma. A new category of FAP-associated lung tumors may be indicated.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary sclerosing haemangioma (PSH) is an uncommon tumour that is composed of glandular/papillary lining cells and polygonal cells. The biological behaviour of this tumour has been investigated; however, the molecular pathogenesis of PSH remains unknown. To characterise the role of the Wnt/beta-catenin pathway in the genesis of PSH. 37 PSH samples were investigated immunohistochemically for detection of the beta-catenin protein and direct sequencing of exon 3 of the beta-catenin gene. Nuclear expression of beta-catenin was found in the lining component of 23 tumours (62%) and in the polygonal component of 11 tumours (30%). The expression of beta-catenin was stronger in the lining component, but weaker in the polygonal component. Interestingly, all the tumours with expression of beta-catenin in the polygonal component also expressed beta-catenin in the lining component. However, mutation of exon 3 of the beta-catenin gene was detected in only one tumour that expressed nuclear beta-catenin in lining and polygonal components. The Wnt/beta-catenin pathway is involved in the genesis of PSH, but mutation of exon 3 of the beta-catenin gene rarely contributes to the activation of the Wnt/beta-catenin pathway in PSH.
    Journal of clinical pathology 04/2008; 61(3):268-71. · 2.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary sclerosing hemangioma is a unique lung neoplasm. It occurs sporadically in middle-aged patients, although cases have been reported in the pediatric population and may be associated with familial adenomatous polyposis.1,2 Sclerosing hemangiomas are typically peripheral and involve lung parenchyma. However, they rarely present as endobronchial polypoid masses resulting in clinical symptoms of bronchial obstruction.3 The lesions have sclerosis and hemorrhagic cystic spaces lined by surface/cuboidal cells thought to be reactive and solid areas consisting of round/polygonal cells thought to be neoplastic. For many years sclerosing hemangioma was thought to be a vascular tumor because of its microscopic appearance, hence the name.
    12/2007: pages 334-340;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sclerosing hemangioma of the lung is an uncommon benign tumour that usually presents as an asymptomatic solitary nodule and affects middle age women. Because there are few findings on radiologic studies that are characteristic of sclerosing hemangioma, it is difficult to diagnose on the basis of imaging and biopsy remains the definitive diagnostic test. We report a case of pulmonary sclerosing hemangioma with extremely unexpected imaging findings and review the literature. KeywordsSclerosing hemangioma-Lung-Computed Tomography-Magnetic Resonance Imaging-Positron Emission Tomography
    Central European Journal of Medicine 5(4):447-451. · 0.26 Impact Factor